Myriad Genetics, Inc. (NASDAQ:MYGN) Director Heinrich Dreismann sold 6,000 shares of the company’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $33.50, for a total value of $201,000.00. Following the sale, the director now owns 33,743 shares of the company’s stock, valued at $1,130,390.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Myriad Genetics, Inc. (NASDAQ MYGN) traded up $0.10 during trading on Wednesday, reaching $32.58. The company’s stock had a trading volume of 529,800 shares, compared to its average volume of 1,180,440. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. Myriad Genetics, Inc. has a 52 week low of $15.15 and a 52 week high of $37.30. The stock has a market capitalization of $2,248.94, a PE ratio of 29.80, a PEG ratio of 2.06 and a beta of 0.25.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.05. The business had revenue of $190.20 million for the quarter, compared to analyst estimates of $183.52 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The company’s revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.23 earnings per share. equities research analysts predict that Myriad Genetics, Inc. will post 1.05 EPS for the current fiscal year.

A number of equities research analysts have commented on MYGN shares. ValuEngine cut Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Morgan Stanley increased their price target on Myriad Genetics from $24.00 to $26.00 and gave the company an “underweight” rating in a research note on Wednesday, November 8th. Deutsche Bank increased their price target on Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Wednesday, November 8th. Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price target for the company in a research note on Tuesday, October 17th. Finally, Leerink Swann reiterated a “market perform” rating and issued a $31.00 price target on shares of Myriad Genetics in a research note on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Myriad Genetics presently has a consensus rating of “Hold” and an average price target of $28.10.

Several hedge funds have recently made changes to their positions in the company. TrimTabs Asset Management LLC increased its holdings in shares of Myriad Genetics by 17.2% in the third quarter. TrimTabs Asset Management LLC now owns 11,798 shares of the company’s stock valued at $427,000 after purchasing an additional 1,728 shares during the period. Shelton Capital Management acquired a new position in shares of Myriad Genetics in the third quarter valued at about $238,000. CS Mckee LP increased its holdings in shares of Myriad Genetics by 42.2% in the third quarter. CS Mckee LP now owns 42,650 shares of the company’s stock valued at $1,543,000 after purchasing an additional 12,650 shares during the period. California Public Employees Retirement System increased its holdings in shares of Myriad Genetics by 3.7% in the third quarter. California Public Employees Retirement System now owns 285,280 shares of the company’s stock valued at $10,321,000 after purchasing an additional 10,280 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Myriad Genetics in the third quarter valued at about $1,028,000.

WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/myriad-genetics-inc-mygn-director-heinrich-dreismann-sells-6000-shares-of-stock/1761320.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with Analyst Ratings Network's FREE daily email newsletter.